DSN Quick Credit: Biosimilars and legislation related to substitution: Pharmacists
Pharmacists in community-based practice.
Universal program number: 0401-0000-17-503-H03-P
CE Broker tracking number: 20-609718
Activity type: Knowledge-based
To provide pharmacists with an overview of legal considerations for the legislation related to substituting biosimilar products.
In this lesson, the legal aspects of biosimilar legislation will be reviewed to provide the learner with up-to-date information.
- Describe the difference between biosimilars, interchangeable products and generic medications.
- Identify state legislation affecting the dispensing of biosimilars.
To obtain credit:
To complete the program and receive CPE credit, view all lesson content and complete the learning assessment by submitting answers online. A minimum test score of 65% is needed to obtain credit. After successfully completing the learning assessment, participants must complete a program evaluation and claim the available CPE credit. Participants also must verify personal information required by CPE monitor and/or CE Broker (for Florida license holders) prior to submitting CPE credit claims. Official statements of credit are available only through CPE Monitor located at NABP.net.
If you have a question, visit our Frequently Asked Questions page.
All other customer service questions should be directed to DRSNCE@lf1925.com.
Drug Store News is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This CPE activity is approved for pharmacists and is worth 0.25 contact hours (0.025 CEUs). The activity is available for CE credit through June 21, 2020.
Jason Kwan, PharmD, and Kellie Manders, JD, attorney, Bula Law/Carpenter Law Firm
Jason Kwan, Kellie Manders and the DSN editorial and continuing education staff do not have any actual or potential conflicts of interest in relation to this lesson.
- 0.25 Pharmacist